ABBV-RGX-314 Dose 3
Sponsors
AbbVie
Conditions
Center-Involved Diabetic Macular Edema (CI-DME)Diabetic Retinopathy (DR)Neovascular Age-Related Macular Degeneration (nAMD)
Phase 2
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Active, not recruitingNCT04514653
Start: 2020-08-25End: 2027-02-01Updated: 2026-02-27
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
Active, not recruitingNCT04567550
Start: 2020-11-20End: 2026-12-31Updated: 2025-09-17